scispace - formally typeset
Search or ask a question

Showing papers on "Monoamine oxidase B published in 2009"


Journal ArticleDOI
TL;DR: The long-term administration of L-dopa in PD patients may produce L- dopa–induced dyskinesia (LID), which may be due to chronic overstimulation of supersensitive DA D1 receptors.

167 citations


Journal ArticleDOI
23 Nov 2009-PLOS ONE
TL;DR: This is one of the first reports that smoking induces an epigenetic modification, and could have a larger impact than cardiovascular damage, considering that MAO-dependent 5-HT catabolism is also involved in addiction, predisposition to cancer, behaviour and mental health.
Abstract: BACKGROUND Postulating that serotonin (5-HT), released from smoking-activated platelets could be involved in smoking-induced vascular modifications, we studied its catabolism in a series of 115 men distributed as current smokers (S), never smokers (NS) and former smokers (FS) who had stopped smoking for a mean of 13 years. METHODOLOGY/PRINCIPAL FINDINGS 5-HT, monoamine oxidase (MAO-B) activities and amounts were measured in platelets, and 5-hydroxyindolacetic acid (5-HIAA)--the 5-HT/MAO catabolite--in plasma samples. Both platelet 5-HT and plasma 5-HIAA levels were correlated with the 10-year cardiovascular Framingham relative risk (P<0.01), but these correlations became non-significant after adjustment for smoking status, underlining that the determining risk factor among those taken into account in the Framingham risk calculation was smoking. Surprisingly, the platelet 5-HT content was similar in S and NS but lower in FS with a parallel higher plasma level of 5-HIAA in FS. This was unforeseen since MAO-B activity was inhibited during smoking (P<0.00001). It was, however, consistent with a higher enzyme protein concentration found in S and FS than in NS (P<0.001). It thus appears that MAO inhibition during smoking was compensated by a higher synthesis. To investigate the persistent increase in MAO-B protein concentration, a study of the methylation of its gene promoter was undertaken in a small supplementary cohort of similar subjects. We found that the methylation frequency of the MAOB gene promoter was markedly lower (P<0.0001) for S and FS vs. NS due to cigarette smoke-induced increase of nucleic acid demethylase activity. CONCLUSIONS/SIGNIFICANCE This is one of the first reports that smoking induces an epigenetic modification. A better understanding of the epigenome may help to further elucidate the physiopathology and the development of new therapeutic approaches to tobacco addiction. The results could have a larger impact than cardiovascular damage, considering that MAO-dependent 5-HT catabolism is also involved in addiction, predisposition to cancer, behaviour and mental health.

138 citations


Journal ArticleDOI
TL;DR: It is suggested that zebrafish MAO resembles mammalian MAO A more than MAO B, metabolizing mainly 5‐HT, and applications of this model of hyperserotonergism include pharmacological and genetic screenings.
Abstract: Serotonin (or 5-hydroxytryptamine; 5-HT) and monoamine oxidase (MAO) are involved in several physiological functions and pathological conditions. We show that the serotonergic system and its development in zebrafish are similar to those of other vertebrates rendering zebrafish a good model to study them. Development of MAO expression followed a similar time course as the 5-HT system. MAO expression and activity were located in or adjacent to serotonergic nuclei and their targets, especially in the ventral hypothalamus. MAO mRNA was detected in the brain from 24 h post-fertilization and histochemical enzyme activity from 42 h post-fertilization. Deprenyl (100 microM) decreased MAO activity 34-74% depending on the age. Inhibition of MAO by deprenyl strongly increased 5-HT but not dopamine and noradrenaline levels. Deprenyl decreased 5-HT-immunoreactivity in serotonergic neurons and induced novel ectopic 5-HT-immunoreactivity neurons in the diencephalon in a manner dependent on 5-HT uptake. Deprenyl administration decreased locomotion, altered vertical positioning and increased heart rate. Treatment with p-chlorophenylalanine normalized 5-HT levels and rescued the behavioral alteration, indicating that the symptoms were 5-HT dependent. These findings suggest that zebrafish MAO resembles mammalian MAO A more than MAO B, metabolizing mainly 5-HT. Applications of this model of hyperserotonergism include pharmacological and genetic screenings.

118 citations


Journal ArticleDOI
TL;DR: This is the first report of increased 3NT levels of a specific tyrosine in a PD model and the first use of MRM mass spectrometry to quantify changes in 3NT modifications at specific sites within a target protein.
Abstract: α-Synuclein is a major component of Lewy bodies, proteinacious inclusions which are a major hallmark of Parkinson’s disease (PD). Lewy bodies contain high levels of nitrated tyrosine residues as determined by antibodies specific for 3-nitrotyrosine (3NT) and via mass spectrometry (MS). We have developed a multiple reaction monitoring (MRM) mass spectrometry method to sensitively quantitate the 3NT levels of specific α-synuclein tyrosine residues. We found a 9-fold increase (relative to controls) in levels of 3NT at Tyr-39 of α-synuclein in an inducible transgenic cellular model of Parkinson’s disease in which monoamine oxidase B (MAO-B) is overexpressed and which emulates several features of PD. Increased nitration of Tyr-39 on endogenous α-synuclein via elevations in MAO-B levels could be abrogated by the addition of deprenyl, a specific MAO-B inhibitor. The increased levels of 3NT was selective for Tyr-39 as no significant increases in 3NT levels were detected at other tyrosine residues present in the p...

107 citations


Journal ArticleDOI
TL;DR: Computational and experimental studies led to the identification and biopharmacological characterization of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate 22b (NW-1772) as an in vitro and in vivo potent and selective MAO-B inhibitor, which might be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases.
Abstract: In an effort to discover novel selective monoamine oxidase (MAO) B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[(m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4 were designed, synthesized, and evaluated as MAO inhibitors. Several compounds with MAO-B inhibitory activity in the nanomolar range and excellent MAO-B selectivity (selectivity index SI > 400) were identified. Structure-affinity relationships and docking simulations provided valuable insights into the enzyme-inhibitor binding interactions at position 4, which has been poorly explored. Furthermore, computational and experimental studies led to the identification and biopharmacological characterization of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate 22b (NW-1772) as an in vitro and in vivo potent and selective MAO-B inhibitor, with rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. On the basis of this preliminary preclinical profile, inhibitor 22b might be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases.

95 citations


Journal ArticleDOI
TL;DR: This work is the first to successfully demonstrate that pretreatment with ALC exerts effective neuroprotection against the MDMA-induced neurotoxicity at the mitochondrial level, reducing carbonyl formation, decreasing mtDNA deletion, improving the expression of the respiratory chain components and preventing the decrease of 5-HT levels in several regions of the rat brain.

82 citations


Journal ArticleDOI
TL;DR: Results suggest that MAO B deficiency may lead to behavioral disinhibition and decreased anxiety-like responses partially through regional increases of PEA levels.

76 citations


Journal ArticleDOI
TL;DR: Dual-target-directed drugs, compounds that inhibit MAO-B and antagonize A2A receptors, may have value in the management of Parkinson’s disease.

70 citations


Journal ArticleDOI
TL;DR: The results suggest a possibility of upregulation of monoaminergic synthesis/degradation and, probably consequential, downregulation of 5HT2Ar in autistic subjects.
Abstract: Disturbances in serotonin (5HT) neurotransmission have been indicated as biological substrates in several neuropsychiatric disorders including autism. Blood 5HT concentrations, elevated in about one-third of autistic subjects, are regulated through the action of peripheral 5HT-associated proteins. We have measured the activity of two platelet 5HT-associated proteins: 5HT transporter (5HTT) and monoamine oxidase B (MAOB), and indirectly studied the activity of 5HT2A receptor (5HT2Ar) in 15 hyperserotonemic (HS) and 17 normoserotonemic (NS) autistic subjects, and 15 healthy controls (C). While mean velocities of 5HTT kinetics did not significantly differ among the groups, significant elevation in the mean velocity of MAOB kinetics was observed in NS subjects and was even more pronounced in HS subjects in comparison to controls. Also, a decrease in adenosine 5′-diphosphate-induced platelet aggregation of borderline significance was observed in NS subjects, compared to C subjects. The results suggest a possibility of upregulation of monoaminergic synthesis/degradation and, probably consequential, downregulation of 5HT2Ar in autistic subjects.

48 citations


Journal ArticleDOI
TL;DR: The greater neuroprotective effect of rasagiline may be associated with the combination of the parent drug and its metabolite, R-aminoindan, with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death.
Abstract: Stress can affect the brain and lead to depression; however, the molecular pathogenesis is unclear. An association between stress and stress-induced hypersecretion of glucocorticoids occurs during stress. Dexamethasone (a synthetic glucocorticoid steroid) has been reported to induce apoptosis and increase the activity of monoamine oxidase (MAO) (Youdim et al. 1989). MAO is an enzyme for the degradation of aminergic neurotransmitters; dopamine, noradrenaline and serotonin and dietary amines and MAO inhibitors are classical antidepressant drugs. In this study, we have compared the ability of rasagiline (Azilect) and its main metabolite, R-aminoindan with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death employing human neuroblastoma SH-SY5Y cells and glioblastoma 1242-MG cells. Dexamethasone reduced cell viability as measured by MTT test, but rasagiline, selegiline, and 1-R-aminoindan could significantly prevent dexamethasone-induced brain cell death. Among three drugs, rasagiline had the highest neuroprotective effect. Furthermore, the inhibitory effects of these drugs on MAO B catalytic activity and on apoptotic DNA damage (TUNEL staining) were examined. Rasagiline exhibited highest inhibition on MAO B enzymatic activity and prevention on DNA damage as compared to selegiline and 1-R-aminoindan. In summary, the greater neuroprotective effect of rasagiline may be associated with the combination of the parent drug and its metabolite 1-R-aminoindan.

46 citations


Journal ArticleDOI
TL;DR: The obtained results demonstrated that the administration of a neurotoxic binge dose of MDMA to an adolescent rat model previously treated with the specific MAO‐A inhibitor, clorgyline, resulted in synergistic effects on serotonin‐ (5‐HT) mediated behaviour and body temperature, provoking high mortality.
Abstract: The administration of a neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') to the rat results in mitochondrial oxidative damage in the central nervous system, namely lipid and protein oxidation and mitochondrial DNA deletions with subsequent impairment of the correspondent protein expression. Although these toxic effects were shown to be prevented by monoamine oxidase B inhibition, the role of monoamine oxidase A (MAO-A) in MDMA-mediated mitochondrial damage remains to be evaluated. Thus, the aim of the present study was to clarify the potential interference of a specific inhibition of MAO-A by clorgyline, on the deleterious effects produced by a binge administration of a neurotoxic dose of MDMA (10 mg MDMA/kg of body weight, intraperitoneally, every 2 hours in a total of four administrations) to an adolescent rat model. The parameters evaluated were mitochondrial lipid peroxidation, protein carbonylation and expression of the respiratory chain protein subunits II of reduced nicotinamide adenine dinucleotide dehydrogenase (NDII) and I of cytochrome oxidase (COXI). Considering that hyperthermia has been shown to contribute to the neurotoxic effects of MDMA, another objective of the present study was to evaluate the body temperature changes mediated by MDMA with a MAO-A selective inhibition by clorgyline. The obtained results demonstrated that the administration of a neurotoxic binge dose of MDMA to an adolescent rat model previously treated with the specific MAO-A inhibitor, clorgyline, resulted in synergistic effects on serotonin- (5-HT) mediated behaviour and body temperature, provoking high mortality. Inhibition of MAO-A by clorgyline administration had no protective effect on MDMA-induced alterations on brain mitochondria (increased lipid peroxidation, protein carbonylation and decrease in the expression of the respiratory chain subunits NDII and COXI), although it aggravated MDMA-induced decrease in the expression of COXI. These results reinforce the notion that the concomitant use of MAO-A inhibitors and MDMA is counter indicated because of the resulting severe synergic toxicity.

Journal ArticleDOI
TL;DR: The results suggest that LPS induces chronic wounds via elevated MAO/B-mediated increases in H(2)O( 2) and TNF-alpha activity by epithelial cells and is further associated with more distant effects on systemic oxidative stress and alveolar bone loss.
Abstract: Reactive oxygen species (ROS) production is an antimicrobial response to pathogenic challenge that may, in the case of persistent infection, have deleterious effects on the tissue of origin. A rat periodontal disease model was used to study ROS-induced chronic epithelial inflammation and bone loss. Lipopolysaccharide (LPS) was applied for 8 weeks into the gingival sulcus, and histological analysis confirmed the onset of chronic disease. Junctional epithelium was collected from healthy and diseased animals using laser-capture microdissection, and expression microarray analysis was performed. Of 19,730 genes changed in disease, 42 were up-regulated ≥4-fold. Three of the top 10 LPS-induced genes, monoamine oxidase B (MAO/B) and flavin-containing monooxygenase 1 and 2, are implicated in ROS signaling. LPS-associated induction of the ROS mediator H2O2, as well as MAO/B and tumor necrosis factor (TNF)-α levels were validated in the rat histological sections and a porcine junctional epithelial cell culture model. Topical MAO inhibitors significantly counteracted LPS-associated elevation of H2O2 production and TNF-α expression in vivo and in vitro, inhibited disease-associated apical migration and proliferation of junctional epithelium and inhibited induced systemic H2O2 levels and alveolar bone loss in vivo. These results suggest that LPS induces chronic wounds via elevated MAO/B-mediated increases in H2O2 and TNF-α activity by epithelial cells and is further associated with more distant effects on systemic oxidative stress and alveolar bone loss.

Journal ArticleDOI
TL;DR: This finding provides the first evidence that MAOB polymorphisms influence levels of negative emotionality in healthy human volunteers, and could lead to a better understanding of personality traits and inter-individual susceptibility developing psychiatric disorders such as major depression.
Abstract: Monoamine oxidase A and B (MAOA and MAOB) appear to be involved in the pathogenesis of Major Depression, and vulnerability of Major Depression is associated with personality traits relating to positive and negative affect This study aimed to investigate associations between MAOA and MAOB polymorphisms and personality traits of positive and negative emotionality in healthy volunteers, to elucidate mechanisms underlying personality and the risk for depression Healthy Caucasian volunteers (N = 150) completed the Multiphasic Personality Questionnaire (MPQ), which includes independent superfactors of Positive Emotionality and Negative Emotionality Participants were genotyped for 8 MAOA and 12 MAOB single nucleotide polymorphisms (SNPs) Association analyses for both SNPs and haplotypes were performed using the permutation approach implemented in PLINK Negative Emotionality was significantly associated with the two highly linked MAOB polymorphisms rs10521432 and rs6651806 (p < 0002) Findings were extended in haplotype analyses For MAOB the 4-SNP haplotype GACG formed from rs1799836, rs10521432, rs6651806 and rs590551 was significantly related to lower Negative Emotionality scores (p < 0002) MAOA was not related to personality in this study Our finding provides the first evidence that MAOB polymorphisms influence levels of negative emotionality in healthy human volunteers If confirmed, these results could lead to a better understanding of personality traits and inter-individual susceptibility developing psychiatric disorders such as major depression

Journal ArticleDOI
TL;DR: Ethan-induced cell death may result from disrupting the movement of GAPDH with the transcriptional activator into the nucleus and secondly inhibit MAO B gene expression, and the neuroprotective effects of rasagiline or 1-R-aminoindan on ethanol- induced cell death mediated by a novel GAPDh-MAO B pathway may provide a new insight in the treatment of neurobiological diseases including alcohol-use disorders.
Abstract: The inhibitors of monoamine oxidase B (MAO B) are effectively used as therapeutic drugs for neuropsychiatric and neurodegenerative diseases. However, their mechanism of action is not clear, since the neuroprotective effect of MAO B inhibitors is associated with the blockage of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-death cascade, rather than the inhibition of MAO B. Here, we provide evidence that GAPDH potentiates the ethanol-induced activity of MAO B and brain cell toxicity. The levels of nuclear GAPDH and MAO B activity are significantly increased in brain-derived cell lines upon 75 mM ethanol-induced cell death. Over-expression of GAPDH in cells enhances ethanol-induced cell death, and also increases the ethanol-induced activation of MAO B. In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 μM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death. In addition, GAPDH interacts with transforming growth factor-beta-inducible early gene (TIEG2), a transcriptional activator for MAO B, and this interaction is increased in the nucleus by ethanol but reduced by MAO B inhibitors and 1-R-aminoindan. Furthermore, silencing TIEG2 using RNAi significantly reduces GAPDH-induced MAO B upregulation and neurotoxicity. In summary, ethanol-induced cell death, attenuated by MAO B inhibitors, may result from disrupting the movement of GAPDH with the transcriptional activator into the nucleus and secondly inhibit MAO B gene expression. Thus, the neuroprotective effects of rasagiline or 1-R-aminoindan on ethanol-induced cell death mediated by a novel GAPDH-MAO B pathway may provide a new insight in the treatment of neurobiological diseases including alcohol-use disorders.

Journal ArticleDOI
TL;DR: Four genes were tested for their impact on five schizophrenia symptom factors: delusions, hallucinations, mania, depression, and negative symptoms, and a significant association between the GABRB3 191 bp allele and the hallucinations factor was detected using QPDTPHASE.

Journal ArticleDOI
TL;DR: Evidence is provided for the first time showing the stimulating effect of RA on MAO B and new insight is provided into the molecular mechanisms ofMAO B regulation by hormones.

Journal ArticleDOI
TL;DR: Molecular docking studies with MAO-B indicate that the increased binding affinity exhibited by the (E)-styrylisatin analogues, in comparison to isatin, is best explained by the ability of the styrylisatins to bridge both the entrance cavity and the substrate cavity of the enzyme.

01 Jan 2009
TL;DR: In this paper, (E)-8-(3-chlorostyryl)caffeine (CSC) is a specific reversible inhibitor of human monoamine oxidase B (MAO-B) and does not bind to human MAO-A.
Abstract: Previous studies have shown that (E)-8-(3-chlorostyryl)caffeine (CSC) is a specific reversible inhibitor of human monoamine oxidase B (MAO-B) and does not bind to human MAO-A. Since the small molecule isatin is a natural reversible inhibitor of both MAO-B and MAO-A, (E)-5-styrylisatin and (E)-6-styrylisatin analogues were synthesized in an attempt to identify inhibitors with enhanced potencies and specificities for MAO-B. The (E)-styrylisatin analogues were found to exhibit higher binding affinities than isatin with the MAO preparations tested. The (E)-5-styrylisatin analogues bound more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity. Molecular docking studies with MAO-B indicate that the increased binding affinity exhibited by the (E)-styrylisatin analogues, in comparison to isatin, is best explained by the ability of the styrylisatins to bridge both the entrance cavity and the substrate cavity of the enzyme. Experimental support for this model is shown by the weaker binding of the analogues to the Ile199Ala mutant of human MAO-B. The lower selectivity of the (E)-styrylisatin analogues between MAO-A and MAO-B, in contrast to CSC, is best explained by the differing relative geometries of the aromatic rings for these two classes of inhibitors.

Journal ArticleDOI
TL;DR: The pteridine-2,4-dione analogues show promise as scaffolds for the development of potent reversible MAO-B inhibitors and as observed in earlier studies, the most potent inhibitors were obtained with 3-chlorostyryl substitution.

Journal ArticleDOI
TL;DR: A series of structurally related N-methyl-2-phenylmaleimidyl analogues has been prepared and evaluated as inhibitors of MAO-B, and the maleimides were more potent competitive inhibitors than the corresponding pyrrolyl analogues.

Journal ArticleDOI
TL;DR: Activity of platelet MAO-B in Parkinson’s patients was increased in naive cases and those treated with L-DOPA alone or in combination with other drugs compared to controls, suggesting action mechanism of drugs used in the treatment of Parkinson‘s disease could be understood by assay of platelemonamine oxidase-B activity.
Abstract: A case-control study was undertaken to investigate the status of platelet monoamine oxidase-B (MAO-B) activity in Indian cases of idiopathic Parkinson’s disease. A significant increase in the activity of platelet MAO-B was observed in Parkinson’s cases (n = 26) as compared to controls (n = 26). No significant change in the activity of the enzyme was observed while the data was analysed with respect to age, sex and duration of disease. A trend of decrease in platelet MAO-B activity was observed in Parkinson’s cases with respect to stage although the change was not significant. No correlation in platelet MAO-B activity was observed with respect to age and sex in the control subjects. Parkinson’s cases treated with L-DOPA and MAO-B inhibitor exhibited decreased platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Interestingly, Parkinson’s cases treated with L-DOPA and amantadine also had lower platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Activity of platelet MAO-B in Parkinson’s patients was increased in naive cases and those treated with L-DOPA alone or in combination with other drugs compared to controls. The results of the present study indicate that phenotypic activity of platelet MAO-B is high in Indian Parkinson’s cases. Further, action mechanism of drugs used in the treatment of Parkinson’s disease could be understood by assay of platelet MAO-B activity. It is an interesting observation and may be looked further in large number of cases.

Journal ArticleDOI
TL;DR: Reduced platelet 5-HT concentrations in hypothyroid patients suggests a complex interaction between the 5- HT system and HPT axis activity, which could be related to the frequent occurrence of depressive symptoms in hyp Timothyroid patients.
Abstract: Background/Aim: The relationship between the hypothalamic-pituitary-thyroid (HPT) axis and the serotonergic (5-hydroxytryptamine, 5-HT) system is not clear. The aim of the study was

Journal ArticleDOI
TL;DR: MAO-B and mAChR sensitivity may not be sufficiently high to assess early, subclinical responses to low/moderate methylmercury and/or PCB exposure, whereas these markers are significantly altered in sustained exposure scenarios, as shown by clinical studies in drug addicts or patients treated with psychopharmacological agents.
Abstract: Experimental evidence suggests that monoamine oxidase B (MAO-B) and muscarinic cholinergic receptors (mAChRs) are involved in the pathogenesis of neurotoxicity caused by methylmercury and polychlorinated biphenyls (PCBs). Blood samples from 7-year-old exposed children were analyzed for platelet MAO-B and lymphocyte mAChRs as potential markers of exposure to these neurotoxicants. The blood neurotoxicity biomarkers were compared with prenatal and current exposures and with neuropsychological test results. Both biomarkers showed homogeneous distributions within this cohort (mAChR, range 0.04–36.78 fmol/million cells; MAO-B, 0.95–14.95 nmol mg−1 protein h−1). No correlation was found between the two biomarkers and either blood neurotoxicant concentrations or clinical findings. MAO-B and mAChR sensitivity may not be sufficiently high to assess early, subclinical responses to low/moderate methylmercury and/or PCB exposure, whereas these markers are significantly altered in sustained exposure scenarios, as shown...

Patent
18 Feb 2009
TL;DR: In this paper, the authors developed a new animal model for Parkinson's disease and discovered that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong prognostic indicator for the disease.
Abstract: This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong prognostic indicator for the disease. Accordingly, in certain embodiments, methods are provided for identifying a mammal at risk for Parkinson's disease. The methods typically involve determining level of expression or activity of monoamine oxidase B (MAO-B) in a sample from the mammal wherein an elevated level of MAO-B expression and/or activity as compared to a control (reference) is an indicator that the mammal has an increased likelihood of developing Parkinson's disease.

Journal ArticleDOI
TL;DR: Rarely repeated episodes of 1-h immobilization in rats were accompanied by an increase in the content of molecular products of lipid peroxidation and decrease in the amount of oxidatively modifi ed proteins.
Abstract: Rarely repeated episodes of 1-h immobilization in rats were accompanied by an increase in the content of molecular products of lipid peroxidation and decrease in the amount of oxidatively modifi ed proteins. Monoamine oxidase B inhibitor deprenyl prevented the poststress activation of lipid peroxidation.

Journal Article
TL;DR: The results of the present study suggest that the increase of dental pulp SSAO activity contributes to the development of inflammation in the dental pulp.
Abstract: BACKGROUND: Human dental pulp contains monoamine oxidase (MAO) and semicarbazide sensitive amine oxidase (SSAO). In other tissues SSAO is involved in oxidative stress and inflammation, but the role of MAO and SSAO in human pulp and changes of their activities in reversible pulpitis still remains poorly understood. MATERIAL/METHODS: We investigated MAO labeling with mechanism-based inhibitor [3H]pargyline activities of MAO A, MAO B, and SSAO in healthy and inflamed human dental pulp. RESULTS: Incubation of human dental pulp homogenates with [3H]pargyline caused MAO labeling. MAO activity assayed with 100 microM [14C]5HT or 10 microM [14C]PEA was sensitive to selective inhibitors of MAO A and MAO B, respectively. MAO activity with 50 microM [14C]PEA was partially inhibited by clorgyline, and total inhibition was achieved only by the combination of clorgyline and semicarbazide, suggesting the presence of SSAO. Inflammation of the dental pulp was accompanied by a significant decrease in MAO labeling, MAO B (but not MAO A) activity and the increase in SSAO activity. CONCLUSIONS: The results of the present study suggest that the increase of dental pulp SSAO activity contributes to the development of inflammation in the dental pulp. The decrease in MAO B activity and lack of significant changes in MAO A activity may be associated with an anti-inflammatory response - inflamed pulp MAO A still effectively deaminates the inflammatory mediator 5HT, whereas inhibition of MAO B could result in some decrease of hydrogen peroxide generation, essential for the tissue damage in inflammation.

Journal ArticleDOI
TL;DR: For the first time, using a double-labeling immunofluorescence histochemical method for laser microscopy, it is reported that no MAOB is found in endothelial cells, hepatic stellate cells, or Kupffer's cells.
Abstract: We used an immunohistochemical method to examine the localization of monoamine oxidase type B (MAOB) in rat liver. At the light microscopic level, MAOB was highly expressed in rat liver. It was intense around portal area, and weak around central area. All the hepatocytes examined had MAOB immunoreactivity. For the first time, using a double-labeling immunofluorescence histochemical method for laser microscopy, we report that no MAOB is found in endothelial cells, hepatic stellate cells, or Kupffer's cells. When examined under transmission electron microscopy, MAOB was localized to the mitochondrial outer membrane of hepatocytes. No apparent localization of MAOB was found in the rough endoplasmic reticulum, the crystal membrane of mitochondria, the nuclear envelope, or the plasma membrane.

Journal ArticleDOI
TL;DR: The quantitative structure-activity relationships for the combined series of indoles and pyrroles were elucidated and the structural conditions to show good inhibitory effects on MAO-A were derived, which can help design new inhibitors irrespective of their specific moiety.
Abstract: Monoamine oxidase A (MAO-A) converts norepinephrine and serotonin to an oxidative form These monoamine neurotransmitters have important roles in depression The MAO-A inhibitors have been discovered for neurodegenerative disease therapy In order to design novel MAO-A inhibitors, in this study, the quantitative structure-activity relationships for the combined series of indoles and pyrroles were elucidated and the structural conditions to show good inhibitory effects on MAO-A were derived This result can help us design new inhibitors irrespective of their specific moiety

Journal Article
TL;DR: This review focuses on multiplicity of monoamine oxidase (MAO) activity in rat hepatic injury, which play a major role in the metabolism of biogenic amines.
Abstract: This review focuses on multiplicity of monoamine oxidase (MAO) activity in rat hepatic injury. MAO play a major role in the metabolism of biogenic amines. Stress such as immobilization stress (IMMO) or cold stress changes the multiple forms of MAO activity in rat liver. Thyroid hormone-inducible MAO inhibitor may play some role in regulating the MAO activity in rat liver. Carcinogen such as dimethylnitrosamine (DEN) might change the proportions of the forms of MAO activity in tumor cells. This compound is selective to and an irreversible inhibitor of MAO-B. These changes may account for the multiplicity of MAO by hepatic injury.

Journal ArticleDOI
TL;DR: Selective anxiolytic afobazole (1 mM) inhibits monoamine oxidase A activity in mitochondria from rat brain and liver and effect of the compound does not depend on the time of preincubation with mitochondria.
Abstract: Selective anxiolytic afobazole (1 mM) inhibits monoamine oxidase A activity in mitochondria from rat brain and liver (IC(50) 0.36 and 0.43, respectively). Effect of the compound does not depend on the time of preincubation with mitochondria. Triple washout of mitochondria is followed by complete recovery of initial enzyme activity.